HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC

Yu, Helena A; Hayashi, Hidetoshi; Goto, Yasushi; Reck, Martin; Yang, James Chih-Hsin; FELIP, ENRIQUETA

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Yu, Helena A
dc.contributor.author	Hayashi, Hidetoshi
dc.contributor.author	Goto, Yasushi
dc.contributor.author	Reck, Martin
dc.contributor.author	Yang, James Chih-Hsin
dc.contributor.author	FELIP, ENRIQUETA
dc.date.accessioned	2023-09-07T10:39:43Z
dc.date.available	2023-09-07T10:39:43Z
dc.date.issued	2023-06
dc.identifier.citation	Yu HA, Chih-Hsin Yang J, Hayashi H, Goto Y, Felip E, Reck M, et al. HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC Clinical Trial Protocol. Futur Oncol. 2023 Jun;19(19):1319–29.
dc.identifier.issn	1479-6694
dc.identifier.uri	https://hdl.handle.net/11351/10250
dc.description	Conjugado anticuerpo-fármaco; Cáncer de pulmón de células no pequeñas; Patritumab deruxtecan
dc.language.iso	eng
dc.publisher	Future Medicine
dc.relation.ispartofseries	Future Oncology;19(19)
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.source	Scientia
dc.subject	Anomalies cromosòmiques
dc.subject	Pulmons - Càncer - Tractament
dc.subject	Immunoglobulines - Ús terapèutic
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	/drug therapy
dc.subject.mesh	Immunoconjugates
dc.subject.mesh	Mutation
dc.title	HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.2217/fon-2022-1250
dc.subject.decs	neoplasias pulmonares
dc.subject.decs	/farmacoterapia
dc.subject.decs	inmunoconjugados
dc.subject.decs	mutación
dc.relation.publishversion	http://dx.doi.org/10.2217/fon-2022-1250
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Yu HA] Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. [Yang JC] Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan. [Hayashi H] Department of Medical Oncology, Kindai University, Osaka, Japan. [Goto Y] Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Reck M] Department of Thoracic Oncology, LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany
dc.identifier.pmid	37212796
dc.identifier.wos	000993497900001
dc.rights.accessrights	info:eu-repo/semantics/openAccess